Weight regain upon discontinuation appears to be a class-wide reality for GLP-1 and related agonists
Even when a peptide is marketed for research or therapeutic interest, it may still be flagged in sports testing if it falls under a prohibited class or produces banned physiological effects
At En Vogue IV Therapy and Wellness, we offer monthly medical weight loss follow-ups to monitor progress, adjust dosing as needed, and support you throughout your journey
Research consistently shows that resistance exercise during GLP-1 agonist-induced weight loss significantly reduces lean mass loss, potentially achieving the same protective effect that tesamorelin growth hormone elevation provides
A 2024 scoping review by Karacabeyli and Lacaille found GLP-1 medications inhibit the NF-kB pathway one of the bodys master inflammation switches in RA and psoriasis cell models, even before weight changes
These symptoms often improve as your body adjusts